Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611042 | 0.82 | IDO1 (0.55) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL20353958 | 0.79 | IDO1 (0.53) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL22079091 | 0.79 | IDO1 (0.53) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL23021781 | 0.79 | IDO1 (0.60) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL28592498 | 0.79 | IDO1 (0.53) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL24368019 | 0.77 | IDO1 (0.54) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL21540839 | 0.77 | IDO1 (0.54) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL12491511 | 0.77 | IDO1 (0.50) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL21216406 | 0.74 | IDO1 (0.51) | IDO1NOS1AXLMETAP2JAK2 | |
| Hydrochloric Acid SCHEMBL13386757 | 0.74 | IDO1 (0.51) | IDO1NOS1AXLMETAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | IDO1 1513/4885NOS1 4455/4885AXL 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.